BIONTECH : Receives a Buy rating from Bryan Garnier marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
The next generation Covid-19 vaccines seeking a slice of the market
A new group of vaccine makers is hoping to challenge the Covid-19 shots that are already household names, sharpening competition in what is set to be the first ever jab market to encompass the entire global population.
BioNTech/Pfizer and Moderna, the pandemic’s mRNA-based vaccine frontrunners, have already booked billions of dollars in revenue, which they are using to boost production, sign new contracts and entrench their positions. Likewise, Oxford/AstraZeneca and Johnson & Johnson have been rolling out their cheaper and easier to transport shots for months, while Chinese and Russian-made vaccines dominate in several markets.
BIONTECH IM FOKUS: Milliardengewinne wecken Begehrlichkeiten « Finanzportal financial de – Aktien – Börse – Kurse – Rohstoffe financial.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financial.de Daily Mail and Mail on Sunday newspapers.
Author Bio
Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.
Despite some good news recently about the coronavirus vaccine it co-developed,
BioNTech (NASDAQ:BNTX) has been hit with a recommendation downgrade.
In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.